Bristol-Myers Squibb (BMY)
51.34
0.63 (1.24%)
At close: Apr 14, 2025, 3:21 PM
1.24% (1D)
| Bid | 51.34 |
| Market Cap | 104.46B |
| Revenue (ttm) | 48.3B |
| Net Income (ttm) | -8.95B |
| EPS (ttm) | -4.41 |
| PE Ratio (ttm) | -11.64 |
| Forward PE | 8.46 |
| Analyst | Hold |
| Ask | 51.35 |
| Volume | 9,073,757 |
| Avg. Volume (20D) | 12,566,537 |
| Open | 51.53 |
| Previous Close | 50.71 |
| Day's Range | 50.55 - 51.53 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.41 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for th...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 1, 1972
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Website https://www.bms.com
Analyst Forecast
According to 15 analyst ratings, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $60, which is an increase of 16.87% from the latest price.
Stock ForecastsNext Earnings Release
Bristol-Myers Squibb is scheduled to release its earnings on Apr 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+3.67%
Bristol-Myers Squibb shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
-2.32%
Bristol-Myers Squibb shares are trading lower. The company announced Phase 2 TRANSCEND FL trial evaluating Breyanzi in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
